Intraday Trading Dynamics and Price Movement
Pfizer Ltd. opened the trading day with a gap up of 2.32%, signalling immediate buying interest. The stock maintained upward momentum, reaching its peak at Rs 5,150, representing an 8.18% rise intraday. This strong price action translated into a day change of 8.39%, significantly outperforming the Sensex, which recorded a modest 0.19% gain on the same day.
Volatility was notably elevated, with an intraday volatility of 20.85% calculated from the weighted average price, indicating active trading and fluctuating price swings. The stock’s movement was supported by its position above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, underscoring a sustained positive technical trend.
Pfizer Ltd. has now recorded gains for two consecutive trading days, accumulating an 11.89% return over this period. This recent rally has outperformed the Pharmaceuticals & Biotechnology sector by 7.65% today, highlighting the stock’s relative strength within its industry.
Fresh entry alert! This Small Cap from Electronics & Appliances sector is already turning heads in our Top 1% club. Get ahead of the market now!
- - New Top 1% entry
- - Market attention building
- - Early positioning opportunity
Market Context and Sector Comparison
The broader market environment on 10 Feb 2026 was positive, with the Sensex opening 144.25 points higher and trading at 84,250.26, a 0.22% increase. The index remains close to its 52-week high of 86,159.02, just 2.27% away, supported by a three-week consecutive rise that has seen a 3.33% gain. Mega-cap stocks led the market advance, contributing to the Sensex’s steady climb.
Within this context, Pfizer Ltd.’s 8.39% gain stands out sharply against the Sensex’s modest rise and the Pharmaceuticals & Biotechnology sector’s more subdued performance. Over the last week, Pfizer has outperformed the Sensex by a wide margin, delivering a 10.79% return compared to the index’s 0.58%. Its one-month gain of 5.92% also eclipses the Sensex’s 0.78% increase.
Longer-term performance metrics show Pfizer Ltd. has delivered a 21.41% return over the past year, well ahead of the Sensex’s 8.94% gain. Year-to-date, the stock has risen 3.56%, contrasting with the Sensex’s decline of 1.17%. However, over three and five years, Pfizer’s returns of 30.35% and 16.76% respectively lag behind the Sensex’s 38.79% and 64.15% gains. Over a decade, Pfizer has appreciated by 139.60%, while the Sensex has more than doubled with a 254.50% increase.
Dividend Yield and Market Capitalisation Insights
At the current price level, Pfizer Ltd. offers a dividend yield of 3.46%, which is considered attractive within the Pharmaceuticals & Biotechnology sector. The company holds a Market Cap Grade of 3, reflecting its mid-tier capitalisation status relative to peers. Despite recent upgrades in trading performance, the company’s Mojo Score stands at 37.0 with a Mojo Grade of Sell, downgraded from Hold as of 29 Dec 2025, indicating cautious sentiment from the rating agency.
The stock’s strong technical positioning above all major moving averages suggests sustained investor interest and a positive momentum trend, even as the broader market maintains a steady bullish stance.
Holding Pfizer Ltd. from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Technical and Trading Summary
Pfizer Ltd.’s trading session on 10 Feb 2026 was characterised by high volatility and strong upward price movement. The stock’s ability to sustain gains above all key moving averages signals robust technical strength. The intraday volatility of 20.85% is indicative of active market participation and dynamic price discovery.
The stock’s performance over multiple time frames reveals a pattern of outperformance relative to the Sensex and sector benchmarks, particularly in the short term. The two-day consecutive gain of 11.89% highlights recent positive momentum, while the 8.39% single-day surge underscores the intensity of buying interest during the session.
Pfizer Ltd.’s market cap grade and dividend yield provide additional context for investors assessing the stock’s valuation and income potential. The current dividend yield of 3.46% remains a notable feature for income-focused market participants.
Overall, Pfizer Ltd.’s intraday high and strong trading session on 10 Feb 2026 reflect a significant market event within the Pharmaceuticals & Biotechnology sector, set against a broadly positive market backdrop.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
